<!DOCTYPE html>
<html>
  <head>
    <title>Parkinson’s disease</title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta charset="utf-8">
    <!-- Bootstrap -->
    <link href="//netdna.bootstrapcdn.com/bootswatch/3.2.0/flatly/bootstrap.min.css" rel="stylesheet" media="screen">
    <link href="/css/site.css" rel="stylesheet" media="screen">
    <link href="/css/syntax.css" rel="stylesheet" media="screen">

    <!-- HTML5 Shim and Respond.js IE8 support of HTML5 elements and media queries -->
    <!-- WARNING: Respond.js doesn't work if you view the page via file:// -->
    <!--[if lt IE 9]>
      <script src="https://oss.maxcdn.com/libs/html5shiv/3.7.0/html5shiv.js"></script>
      <script src="https://oss.maxcdn.com/libs/respond.js/1.3.0/respond.min.js"></script>
    <![endif]-->
<script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-48968311-4', 'jandecaluwe.com');
  ga('send', 'pageview');

</script>
  </head>

  <body>

    <!-- Fixed navbar -->
    <div class="navbar navbar-default navbar-fixed-top">
      <div class="container">
        <div class="navbar-header">
          <button type="button" class="navbar-toggle" data-toggle="collapse" data-target=".navbar-collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </button>
          <a class="navbar-brand" href="/">Rory’s notes</a>
        </div>
        <div class="navbar-collapse collapse">

          <ul class="nav navbar-nav navbar-left">
 
          </ul>

          <ul class="nav navbar-nav navbar-right">
            <li class="active"><a href="/notes/">notes</a></li>
          </ul>

        </div><!--/.nav-collapse -->
      </div>
    </div>


<div class="container">

  <ol class="breadcrumb">
    <li><a href="/">Home</a></li>
      <li><a href="/notes/">notes</a></li>
      <li><a href="/notes/neurology/">neurology</a></li>
      <li class="active">Parkinson’s disease</li>
  </ol>

  <div class="page-header">
 
    <h1>Parkinson’s disease</h1>
  </div>

  <div class="row">

    <div class="col-md-3" role="navigation"> 
 
      <div class="sidebar" data-spy="affix" data-offset-top="80" data-offset-bottom="60">
        <div class="well">
          <a href="#"><strong>Parkinson’s disease</strong></a>
          <div class="toc">
<ul>
<li><a href="#braak-theory">Braak theory</a></li>
<li><a href="#epidemiology-genetics">epidemiology + genetics</a></li>
<li><a href="#features">Features</a><ul>
<li><a href="#characteristic-symptoms">Characteristic symptoms:</a></li>
<li><a href="#examination">Examination</a></li>
</ul>
</li>
<li><a href="#diagnosis">Diagnosis</a></li>
<li><a href="#management">Management</a><ul>
<li><a href="#non-pharmalogical">non-pharmalogical</a><ul>
<li><a href="#exercise">Exercise</a></li>
<li><a href="#occupational-therapy">Occupational therapy</a></li>
<li><a href="#speech-therapy">Speech therapy</a></li>
<li><a href="#dietician">Dietician</a></li>
<li><a href="#parkinsons-nz-website">Parkinson’s NZ website</a></li>
<li><a href="#counselling-for-the-patient">counselling for the patient</a></li>
</ul>
</li>
<li><a href="#pharmacological-treatment">Pharmacological treatment</a><ul>
<li><a href="#when-to-start">When to start</a></li>
<li><a href="#levodopa-dopa-decarboxylase-inhibitor">Levodopa + dopa-decarboxylase inhibitor</a></li>
<li><a href="#patients-over-40">Patients over 40:</a></li>
<li><a href="#patients-40">Patients \&lt;40</a></li>
<li><a href="#maoi-b">MAOi-B</a></li>
<li><a href="#amantadine">Amantadine</a></li>
<li><a href="#catechol-o-methyltransferase-inhibitor-may-be-added-later-in-treatment">Catechol-O-methyltransferase inhibitor may be added later in treatment</a></li>
</ul>
</li>
</ul>
</li>
<li><a href="#non-motor-sympotms">Non-motor sympotms</a><ul>
<li><a href="#cardiovascular">Cardiovascular</a></li>
<li><a href="#gastrointestinal">Gastrointestinal</a></li>
</ul>
</li>
</ul>
</div>

        </div>
      </div>
    </div>
 
    <div class="content">
      <div class="col-md-6" role="main">
        <blockquote>
<p>neurodegenerative disorder</p>
<p>severe loss of pigmented dopaminergic neurons in substantia nigra of midbrain</p>
<p>neurons project to corpus striatum - leads to overall decrease in motor activity</p>
<p>not fatal in itself but: falls, #, chest infections 2ary swallowing disorder - increase mortality in PD</p>
</blockquote>
<h3 id="braak-theory">Braak theory</h3>
<ul>
<li>
<p>pathology first starts in eneteric nervous systme and in medulla and olfactory bulb</p>
</li>
<li>
<p>then to substantia nigra</p>
</li>
<li>
<p>precede motor symptoms;</p>
<ul>
<li>
<p>constipation and other autonomic symptoms </p>
<ul>
<li>
<p>sweating </p>
</li>
<li>
<p>drooling @ night</p>
</li>
<li>
<p>erectile dysfunction</p>
</li>
</ul>
</li>
<li>
<p>Hyposmia (decrease smell)</p>
</li>
<li>
<p>REM sleep disorder</p>
</li>
<li>
<p>severe depressive disorder</p>
</li>
<li>
<p>fatigue and/or mental infelxibility</p>
</li>
<li>
<p>lower back pain</p>
</li>
</ul>
</li>
</ul>
<h3 id="epidemiology-genetics">epidemiology + genetics</h3>
<ul>
<li>
<p>1% > 65</p>
<ul>
<li>3/1000 patients</li>
</ul>
</li>
<li>
<p>median age onset = 60yo</p>
</li>
<li>
<p>life expectacy \~ 15yrs</p>
</li>
</ul>
<h3 id="features">Features</h3>
<h4 id="characteristic-symptoms">Characteristic symptoms:</h4>
<ul>
<li>
<p>stiffness</p>
</li>
<li>
<p>resting tremor</p>
</li>
<li>
<p>bradykinesia</p>
<ul>
<li>
<p>handwriting</p>
<ul>
<li>typically slopes upwards</li>
</ul>
</li>
</ul>
</li>
<li>
<p>hypokinesia (reduction of movement)</p>
</li>
<li>
<p>asymetric</p>
</li>
<li>
<p>insidious</p>
</li>
<li>
<p>non motor;</p>
<ul>
<li>
<p>excessive sweating</p>
</li>
<li>
<p>deression</p>
</li>
<li>
<p>reduced sense of smell</p>
</li>
<li>
<p>cognitive impairment</p>
<ul>
<li>alterante = lewy body dementia</li>
</ul>
</li>
<li>
<p>hypotension (?)</p>
<ul>
<li>early hypotension = MSA</li>
</ul>
</li>
<li>
<p><strong>not useful in diagnosing PD limited specificity</strong></p>
</li>
</ul>
</li>
</ul>
<h4 id="examination">Examination</h4>
<ul>
<li>
<p>rigidity</p>
<ul>
<li>
<p>passive movements</p>
</li>
<li>
<p>‘cogwheel phenomenon</p>
</li>
</ul>
</li>
<li>
<p>resting tremor</p>
<ul>
<li>
<p>4Hz (4 cycles / sec)</p>
</li>
<li>
<p>typically affecting upper limb</p>
</li>
</ul>
</li>
<li>
<p>impairment of dextrous upper limb movements and facial expression due to bradykinesia</p>
<ul>
<li>
<p>affecting small muscle groups of face and hands</p>
<ul>
<li>usually seen in the early phases of the condition</li>
</ul>
</li>
</ul>
</li>
<li>
<p>gait disorder</p>
<ul>
<li>
<p>later in course</p>
</li>
<li>
<p>lack of spontaneous arm swing</p>
</li>
<li>
<p>turning <em>en bloc</em></p>
<ul>
<li>whole body turns when changing direction</li>
</ul>
</li>
<li>
<p>festinating gait</p>
<ul>
<li>
<p>small steps</p>
</li>
<li>
<p>shiffling</p>
</li>
</ul>
</li>
<li>
<p>falls </p>
</li>
</ul>
</li>
</ul>
<h3 id="diagnosis">Diagnosis</h3>
<ul>
<li>
<p>diagnosis = challenging</p>
</li>
<li>
<p>recommend specialist opinion (neurology vs. geriatrician) before treatment is initiated</p>
<ul>
<li>improve likelifood of a good outcome</li>
</ul>
</li>
<li>
<p>response to levodopa = key criterion for diagnosis of PD</p>
</li>
<li>
<p>alternative dx</p>
<ul>
<li>
<p>medicine-induced parkinsonism</p>
</li>
<li>
<p>essential tremor</p>
</li>
<li>
<p>multiple cerebral infarction</p>
</li>
</ul>
</li>
</ul>
<h3 id="management">Management</h3>
<blockquote>
<p>no cure</p>
<p>symptom  control</p>
<p>treatment = functional benefit for at least 10yrs</p>
</blockquote>
<h4 id="non-pharmalogical">non-pharmalogical</h4>
<blockquote>
<p>multidisciplinary approach”</p>
<ul>
<li>
<p>PT</p>
</li>
<li>
<p>OT</p>
</li>
<li>
<p>Speach language</p>
</li>
<li>
<p>nurse</p>
</li>
<li>
<p>specialist</p>
</li>
<li>
<p>GP</p>
</li>
</ul>
</blockquote>
<h5 id="exercise">Exercise</h5>
<ul>
<li>
<p>formal exercise rehabilitation likely to benefit patients</p>
</li>
<li>
<p>PT specific interventions</p>
<ul>
<li>
<p>start hesitancy</p>
</li>
<li>
<p>freezing of gait </p>
</li>
<li>
<p>festination</p>
</li>
<li>
<p>fals</p>
</li>
</ul>
</li>
<li>
<ol>
<li>
<p>Strategy training</p>
</li>
<li>
<p>Managmeent of musculskeletal issues</p>
<ol>
<li>
<p>weakness</p>
</li>
<li>
<p>loss of ROM</p>
</li>
</ol>
</li>
<li>
<p>General promotion of physical activity with specific interventions for falls prevention</p>
</li>
</ol>
</li>
</ul>
<blockquote>
<p>no evidence that one measure better than any others; quality of comparisons were poor </p>
</blockquote>
<h5 id="occupational-therapy">Occupational therapy</h5>
<ul>
<li>
<p>safely maintain activity and employment</p>
</li>
<li>
<p>improve self esteem</p>
</li>
<li>
<p>also to determine re driving motor vehicle</p>
</li>
</ul>
<blockquote>
<p>Driving:</p>
<p>cognitive disturbance, adverse effect of dopaminergic treatment (daytime sleepiness)</p>
<p>limb strenght, accuracy of rapid foot movements, joint proprioception should be assessed</p>
<p>should always cease if there is doubt about a person’s ability to control a vehicle in an emergency situation</p>
<p><strong> if trouble walking then trouble driving </strong></p>
</blockquote>
<h5 id="speech-therapy">Speech therapy</h5>
<ul>
<li>
<p>hypophonia (soft speech)</p>
</li>
<li>
<p>voice training can improve voice quality and audibility</p>
</li>
<li>
<p>SLT - focus on iincrease on volume of speech</p>
</li>
<li>
<p>dysphagia</p>
</li>
</ul>
<h5 id="dietician">Dietician</h5>
<ul>
<li>
<p>weight loss - some people</p>
<ul>
<li>
<p>extra energy expenditure</p>
<ul>
<li>
<p>tremor/rigidity</p>
</li>
<li>
<p>change swallowing</p>
</li>
<li>
<p>satiety</p>
</li>
<li>
<p>reduced appetite due to dopaminergic treatment</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>may benefit from high calorie supp. but little evidence</p>
</li>
</ul>
<h5 id="parkinsons-nz-website">Parkinson’s NZ website</h5>
<p><a href="www.parkinsons.org.nz">www.parkinsons.org.nz</a></p>
<h5 id="counselling-for-the-patient">counselling for the patient</h5>
<ul>
<li>
<p>can assis in the development of self-management techniques - depression and anxiety</p>
</li>
<li>
<p>strain on families</p>
</li>
</ul>
<h4 id="pharmacological-treatment">Pharmacological treatment</h4>
<ul>
<li>
<p>motor symptoms tycially respond well</p>
<ul>
<li>response = diagnositc criteria</li>
</ul>
</li>
<li>
<p>motor symptoms controlled = on</p>
</li>
<li>
<p>poor motor symptom control = offf</p>
</li>
<li>
<p>little evidence that treatment in early phases results in improved long-term outcomes</p>
</li>
<li>
<p>if doens’t respond consider other diagnosis</p>
</li>
<li>
<p>motor fluctuations</p>
<ul>
<li>dyskinesia 2ary levodopa treatment develop in all patients with PD</li>
</ul>
</li>
<li>
<p>‘wearing off’ phenomenon</p>
<ul>
<li>
<p>increase stiffness adn slowness after dose of med</p>
</li>
<li>
<p>very severe fluctuations between rigid-akinetic states adn severe episodes of dyskinetic (involuntary) movements</p>
</li>
</ul>
</li>
</ul>
<h5 id="when-to-start">When to start</h5>
<ul>
<li>
<p>reports troubling sympomts</p>
</li>
<li>
<p>neurologist/geriatrician responsible for initiating treatment</p>
</li>
<li>
<p>diagnostic trials not considered without discussion with a neurologist or geriatrician</p>
</li>
<li>
<p>if delay -> phone</p>
</li>
</ul>
<h5 id="levodopa-dopa-decarboxylase-inhibitor">Levodopa + dopa-decarboxylase inhibitor</h5>
<ul>
<li>
<p>usually firstline</p>
</li>
<li>
<p>dopamine doesn’t cross b-b barrier - causes severe N&amp;V when given at high doses (enought to cause motor effect)</p>
</li>
<li>
<p>Levodopa does cross </p>
<ul>
<li>
<p>rapidly metabolised to dopamine by decarboxylase - in peripehry as well as in brain</p>
<ul>
<li>
<p>therefore must be administered with peripheral decarboxylase inhibitor</p>
</li>
<li>
<p>carbidopa or beserazide</p>
</li>
</ul>
</li>
</ul>
</li>
</ul>
<h5 id="patients-over-40">Patients over 40:</h5>
<ul>
<li>
<p>combination levodopa = first line</p>
</li>
<li>
<p>swallowed whole - not halved or broken</p>
</li>
<li>
<p>often need to increase doses of levodopa or add dopamine agonists</p>
</li>
<li>
<p>dose sdjusted according to level of diability</p>
</li>
<li>
<p>severity of patient’s dyskinesias often determine maximum dose and length of time that levodopa can be tolerated</p>
</li>
<li>
<p>modified release doesn’t reduce motor fluctuations</p>
</li>
</ul>
<h5 id="patients-40">Patients \&lt;40</h5>
<ul>
<li>
<p>dopamine agoinist</p>
</li>
<li>
<p>b/c likelifood developing motor fluctuations within 5yrs = 100%</p>
<ul>
<li>
<p>ropinirole or pramipexole</p>
</li>
<li>
<p>also frequently used in combination wiht levodopa</p>
</li>
<li>
<p>‘smooth-out’ motor fluctuations</p>
</li>
<li>
<p>cause more sleepiness</p>
</li>
<li>
<p>impulse control disorders</p>
<ul>
<li>
<p>binge eating</p>
</li>
<li>
<p>compulsive shopping</p>
</li>
<li>
<p>gambling</p>
</li>
<li>
<p>hypersexuality</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>bromocriptime/pergolide (ergot-derived)</p>
<ul>
<li>
<p>no longer prescribed due to possibility of cardicac valvular fibrosis, pulmonary fibrosis, retroperiotoneal fibrosis</p>
</li>
<li>
<p>need to be monitored for these complications</p>
</li>
</ul>
</li>
</ul>
<h5 id="maoi-b">MAOi-B</h5>
<ul>
<li>
<p>mild symptoms</p>
</li>
<li>
<p>Selegiline</p>
<ul>
<li>
<p>can delay need for levodopa</p>
</li>
<li>
<p>alone or combination</p>
</li>
<li>
<p>inhibits catabolism of dopamine</p>
</li>
<li>
<p>may also be combined with levodopa</p>
</li>
</ul>
</li>
</ul>
<h5 id="amantadine">Amantadine</h5>
<ul>
<li>
<p>weak dopamine agonist</p>
</li>
<li>
<p>can be used to treat dyskinesia</p>
</li>
<li>
<p>not first-line</p>
</li>
<li>
<p>modest effect</p>
</li>
<li>
<p>last less htan 8 months</p>
<ul>
<li>although recent trial suggests may last for several years</li>
</ul>
</li>
</ul>
<h5 id="catechol-o-methyltransferase-inhibitor-may-be-added-later-in-treatment">Catechol-O-methyltransferase inhibitor may be added later in treatment</h5>
<ul>
<li>
<p>end-of-dose deterioration</p>
</li>
<li>
<p>COMT inhibitors - entacapone, tolcapone</p>
</li>
<li>
<p>prevent peripheral conversion</p>
</li>
</ul>
<p>antimuscarninc medicines less effective compared to dpopaminergic treatments</p>
<h3 id="non-motor-sympotms">Non-motor sympotms</h3>
<h4 id="cardiovascular">Cardiovascular</h4>
<ul>
<li>
<p>postural and post prandial hypotension</p>
<ul>
<li>
<p>increase fluid/salt</p>
</li>
<li>
<p>frequent small meals</p>
</li>
<li>
<p>compression stocking</p>
</li>
<li>
<p>anti-hypertensive meidicnes used with caution</p>
</li>
<li>
<p>fludrocortisone 50mcg daily</p>
</li>
</ul>
</li>
</ul>
<h4 id="gastrointestinal">Gastrointestinal</h4>
<ul>
<li>
<p>Drooling</p>
<ul>
<li>
<p>dopaminergic/antimuscarinic medicines</p>
<ul>
<li>
<p>reduce drooling</p>
</li>
<li>
<p>usually cause adverse effects</p>
</li>
<li>
<p>1% atropine eye drops administered sublingually</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>dysphagia</p>
<ul>
<li>
<p>partially responsive to dopaminergic </p>
</li>
<li>
<p>thickened fluids reduce risk of aspiration</p>
</li>
<li>
<p>SLT</p>
</li>
</ul>
</li>
<li>
<p>gastroparesis</p>
<ul>
<li>
<p>eat small meals</p>
</li>
<li>
<p>domperidone 10-20mg tds/qds</p>
<ul>
<li>dopamine antagonist that doesn’t cross B-B barrier</li>
</ul>
</li>
</ul>
</li>
<li>
<p>constipation</p>
<ul>
<li>
<p>increase fluid/fibre</p>
</li>
<li>
<p>laxatives</p>
</li>
<li>
<p>bisacodyl (stimulant)</p>
</li>
<li>
<p>glycerol supp</p>
</li>
<li>
<p>docusate </p>
</li>
<li>
<p>docusate + sennosides shouldn’t be takien for long periods</p>
</li>
</ul>
</li>
<li>
<p>pain</p>
<ul>
<li>
<p>pain present during On or off</p>
<ul>
<li>adjusting dopamimnergic treatment may provide benefit</li>
</ul>
</li>
<li>
<p>can be caused by restricted movmeent</p>
</li>
<li>
<p>muscle spasm</p>
</li>
<li>
<p>nortrip/amitrip</p>
</li>
<li>
<p>carbamazepine 100mg od or bd - increase according to response</p>
</li>
<li>
<p>gabapentin - max 3.6g</p>
</li>
</ul>
</li>
<li>
<p>Cognitive</p>
<ul>
<li>
<p>anxiety</p>
<ul>
<li>“off” state anxiety may benefit from increase dopaminaergic treatment</li>
</ul>
</li>
<li>
<p>depression</p>
<ul>
<li>
<p>assess for pain or sleep disturbance</p>
</li>
<li>
<p>TCA/SSRI may be appropriate</p>
</li>
<li>
<p>support and counselling</p>
</li>
</ul>
</li>
<li>
<p>Hallucinations</p>
<ul>
<li>
<p>non-troubling don’t require treatment</p>
</li>
<li>
<p>Quetiapine may be used with extreme caution</p>
</li>
</ul>
</li>
<li>
<p>Dementia</p>
<ul>
<li>
<p>clozpaine</p>
<ul>
<li>requires weekly FBC</li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>genitourinary</p>
<ul>
<li>
<p>Urgency/frequnecy/bocturia/incovontinence</p>
<ul>
<li>
<p>avoid diuretic</p>
</li>
<li>
<p>oxybutyinin in cautino</p>
</li>
</ul>
</li>
</ul>
</li>
<li>
<p>Sleep</p>
<ul>
<li>
<p>excessive daytime sleepiness</p>
<ul>
<li>
<p>fatigue 1/3 of PD</p>
</li>
<li>
<p>less common taking levodopa compared to dopamine agonists</p>
</li>
</ul>
</li>
<li>
<p>nocturnal doses of dopaminergic medicine may assis t with insomnia</p>
</li>
<li>
<p>levodopa and dopamine agonists may help pateinets wiht RLS</p>
</li>
<li>
<p>Methylphenidate 1-mg tds may be useful</p>
</li>
<li>
<p>benzodiazepine may be effective for patients with REM sleep disorder</p>
</li>
</ul>
</li>
</ul>
      </div>
    </div>

  </div>
    

    <div class="footer">
        <p>Website powered by <a href="http://urubu.jandecaluwe.com">Urubu</a></p>
    </div>


</div> 


    <!-- jQuery (necessary for Bootstrap's JavaScript plugins) -->
    <script src="https://code.jquery.com/jquery.js"></script>
    <!-- Include all compiled plugins (below), or include individual files as needed -->
    <script src="//netdna.bootstrapcdn.com/bootstrap/3.2.0/js/bootstrap.min.js"></script>

  </body>
</html>
